SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-23-038625
Filing Date
2023-10-30
Accepted
2023-10-30 09:22:15
Documents
3
Period of Report
2023-10-30

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm DEF 14A 413435
2 formdef14a_001.jpg GRAPHIC 344094
3 formdef14a_002.jpg GRAPHIC 262656
  Complete submission text file 0001493152-23-038625.txt   1250345
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 001-40388 | Film No.: 231357750
SIC: 2834 Pharmaceutical Preparations